			Home About us Contact

Frequent Administration (frequent + administration)

Distribution by Scientific Domains

Medical Sciences	75%

Selected Abstracts

Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders

MEDICINAL RESEARCH REVIEWS, Issue 4 2001
M.M. SinghArticle first published online: 12 JUN 200
Abstract DL -Centchroman (67/20; INN: Ormeloxifene)1,2 synthesized at the Central Drug Research Institute, Lucknow, is a nonsteroidal once-a-week oral contraceptive. It was introduced in Delhi in July, 1991,3,5 marketed in India in 1992 as Saheli and Choice-7 (Hindustan Latex Ltd., Thiruvananthapuram) and Centron (Torrent Pharmaceuticals India Ltd., Ahmedabad),4,6 and included in the National Family Welfare Programme in 1995.5 According to post-marketing surveillance,5 ,100,000 women were using this pill and ,1100,000 menstrual cycles were covered until 1996. It is a unique need-oriented contraceptive being effective when taken immediately after coitus or routinely as a weekly pill2,5,19 and has the advantage of less frequent administration. Its contraceptive action is quickly reversible. It has long terminal serum halflife of 168,hr in women and exhibits duration of anti-implantation/estrogen antagonistic action of 120,hr, despite a short (24.1,hr) serum halflife, in the rat. In lactating women, it is excreted in milk in quantities considered unlikely to cause any deleterious effect on suckling babies.20,21 In phase II and III multicentric trials as a contraceptive, children born of method-and-user failure pregnancies showed normal milestones, without any congenital anomaly. Reports of its promising action in the management of certain hormone-related clinical disorders are available. It has an excellent therapeutic index and is considered safe for chronic administration. © 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 4, 302,347, 2001 [source]

Central anticholinergic syndrome secondary to atropine treatment of organophosphate poisoning,

PSYCHOGERIATRICS, Issue 3 2006
AN EROL, Demet DO
Abstract Anticholinergic syndrome is a common phenomenon because of the frequent administration of atropine in organophosphate poisoning. This diagnosis should be considered in patients with altered mental state following therapy with atropine. We report a case of delirium 48 h after atropine treatment for organophosphate poisoning. [source]

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

EUROPEAN JOURNAL OF IMMUNOLOGY, Issue 3 2008
Gunther Spohn
Abstract IL-1 is an important mediator of inflammation and a major cause of tissue damage in rheumatoid arthritis (RA). Therapeutic administration of recombinant IL-1 receptor antagonist (IL-1Ra) is efficacious in reducing clinical symptoms of disease, but suffers from several drawbacks, including the need for frequent administrations of large amounts. Here, we show that immunization of mice with either IL-1, or IL-1, chemically cross-linked to virus-like particles (VLP) of the bacteriophage Q, elicited a rapid and long-lasting autoantibody response. The induced Ab efficiently neutralized the binding of the respective IL-1 molecules to their receptors in vitro and their pro-inflammatory activities in vivo. In the collagen-induced arthritis model, both vaccines strongly protected mice from inflammation and degradation of bone and cartilage. Moreover, immunization with either vaccine showed superior efficacy than daily administrations of high amounts of IL-1Ra. In the T and B cell-independent collagen Ab transfer model, immunization with the IL-1, vaccine strongly protected from arthritis, whereas immunization with the IL-1, vaccine had no effect. Our results suggest that active immunization with IL-1,, and especially IL-1, conjugated to Q, VLP, might become an efficacious and cost-effective new treatment option for RA and other systemic IL-1-dependent inflammatory disorders. [source]

Travelling for radiation cancer treatment: Patient perspectives

PSYCHO-ONCOLOGY, Issue 7 2003
Margaret I. Fitch
Radiation treatment for cancer requires patients to receive frequent administrations and attend the treatment facility on a daily basis for several weeks. Travelling for radiation treatment has the potential to add to the distress an individual may be feeling. This study utilized in-depth interviews to capture 118 patients' perspectives about travelling for cancer treatment. Four themes emerged during the analysis of the data: (1) waiting was the most difficult part of the experience; (2) the idea of travelling for treatment was distressing; (3) travelling for treatment was tiring and posed difficulties for patients; and (4) being away from home had both benefits and drawbacks. Given the inevitability of travelling for radiation treatment, and the issues that arises for patients, supportive strategies need to be designed and implemented. Copyright © 2003 John Wiley & Sons, Ltd. [source]